Dicerna Pharmaceuticals
Dicerna Pharmaceuticals Inc (Form: 8-K, Received: 07/12/2017 16:07:32)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 11, 2017

 

 

DICERNA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36281   20-5993609

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

87 Cambridgepark Drive

Cambridge, MA 02140

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (617) 621-8097

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

At the Company’s Annual Meeting of Stockholders on July 11, 2017 (the “Annual Meeting”), the following actions were taken. The proposals below are described in detail in the Company’s definitive proxy statement dated May 23, 2017 for the Annual Meeting.

Proposal 1

The nominees for election as directors, each for a one-year term, were elected based upon the following votes:

 

Nominee

   For      Against      Abstain      Broker
Non-Votes
 

Douglas M. Fambrough, III, Ph.D.

     26,366,856        18,421        4,058        5,587,385  

Martin Freed, M.D.

     26,366,856        18,421        4,058        5,587,385  

Brian K. Halak, Ph.D.

     26,366,856        18,421        4,058        5,587,385  

Stephen J. Hoffman, M.D., Ph.D.

     26,366,856        18,421        4,058        5,587,385  

Peter Kolchinsky, Ph.D.

     26,366,856        18,421        4,058        5,587,385  

Adam M. Koppel, M.D., Ph.D.

     26,366,756        18,521        4,058        5,587,385  

Dennis H. Langer, M.D., J.D.

     26,366,956        18,321        4,058        5,587,385  

David M. Madden

     26,366,956        18,321        4,058        5,587,385  

Bruce Peacock

     26,366,856        18,421        4,058        5,587,385  

Proposal 2

The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017 was approved based upon the following votes:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

31,967,439    5,027    4,254    —  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 12, 2017     DICERNA PHARMACEUTICALS, INC.
    By:  

/s/ Douglas M. Fambrough, III, Ph.D.

      Douglas M. Fambrough, III, Ph.D.
      Chief Executive Officer